FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1840478974> ?p ?o ?g. }

• W1840478974 endingPage "2195" @default.
• W1840478974 startingPage "2187" @default.
• W1840478974 abstract "We used population pharmacokinetic-parameter estimates and designed a fixed dosing schedule to maintain plasma suramin concentrations between 100 and 300 micrograms/mL and then evaluated its performance.On day 1, patients received a 200-mg test dose and 1,000-mg/m2 loading dose. On days 2, 3, 4, and 5, patients received 1-hour infusions of 400, 300, 250, and 200 mg/m2, respectively. Subsequent 1-hour infusions of 275 mg/m2 were given on days 8, 11, 15, 19, 22, 29, 36, 43, 50, 57, 67, and 78. Therapy was discontinued for dose-limiting toxicity (DLT) or progressive disease (PD). Patients were to be removed from the fixed dosing schedule if, after day 5, three consecutive peak plasma suramin concentrations were greater than 300 micrograms/mL.Forty-two patients, including 40 with hormone-refractory prostate cancer (HRPC), received 700 infusions. Forty patients were assessable for toxicity; 38 were assessable for response. Two patients with preexisting pulmonary disease died early of respiratory insufficiency. Treatment was discontinued in five patients due to DLT and in seven due to PD. No patient had treatment discontinued due to repeated peak plasma suramin concentrations > or = 300 micrograms/mL. The fixed dosing schedule was precise, unbiased, and well tolerated. DLT consisted of grade 4 nephrotoxicity (n = 2), neurotoxicity (n = 2), and corticosteroid-induced psychosis (n = 1). Three patients, who received all 18 doses of suramin per protocol, developed severe, but not dose-limiting, malaise, fatigue, and lethargy. Twenty-four of 36 assessable patients with elevated serum prostate-specific antigen (PSA) levels had a > or = 50% reduction, lasting more than 4 weeks, and 18 had a > or = 75% reduction, lasting more than 4 weeks. Twelve of 23 (52%) symptomatic HRPC patients noted a subjective improvement in pain. There were no measurable responses in four patients with measurable disease. The estimated median survival time in 38 assessable patients with HRPC was 18.8 months. The estimated median time to progression in 35 patients, for whom data were available, was 10.1 months.This easily implemented schedule allowed suramin to be administered safely as an intermittent bolus injection. Toxicity was manageable and reversible." @default.
• W1840478974 created "2016-06-24" @default.
• W1840478974 creator A5012074439 @default.
• W1840478974 creator A5013411266 @default.
• W1840478974 creator A5020274632 @default.
• W1840478974 creator A5028015088 @default.
• W1840478974 creator A5040901194 @default.
• W1840478974 creator A5052340302 @default.
• W1840478974 date "1995-09-01" @default.
• W1840478974 modified "2023-10-18" @default.
• W1840478974 title "Development and validation of a pharmacokinetically based fixed dosing scheme for suramin." @default.
• W1840478974 cites W1562894382 @default.
• W1840478974 cites W1968614309 @default.
• W1840478974 cites W2025012785 @default.
• W1840478974 cites W2055869196 @default.
• W1840478974 cites W2104615180 @default.
• W1840478974 cites W2140867514 @default.
• W1840478974 cites W2161654899 @default.
• W1840478974 cites W2204115562 @default.
• W1840478974 cites W2232475418 @default.
• W1840478974 cites W2242063705 @default.
• W1840478974 cites W2470050007 @default.
• W1840478974 cites W94749320 @default.
• W1840478974 doi "https://doi.org/10.1200/jco.1995.13.9.2187" @default.
• W1840478974 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7666077" @default.
• W1840478974 hasPublicationYear "1995" @default.
• W1840478974 type Work @default.
• W1840478974 sameAs 1840478974 @default.
• W1840478974 citedByCount "54" @default.
• W1840478974 countsByYear W18404789742014 @default.
• W1840478974 crossrefType "journal-article" @default.
• W1840478974 hasAuthorship W1840478974A5012074439 @default.
• W1840478974 hasAuthorship W1840478974A5013411266 @default.
• W1840478974 hasAuthorship W1840478974A5020274632 @default.
• W1840478974 hasAuthorship W1840478974A5028015088 @default.
• W1840478974 hasAuthorship W1840478974A5040901194 @default.
• W1840478974 hasAuthorship W1840478974A5052340302 @default.
• W1840478974 hasConcept C112705442 @default.
• W1840478974 hasConcept C126322002 @default.
• W1840478974 hasConcept C126894567 @default.
• W1840478974 hasConcept C141071460 @default.
• W1840478974 hasConcept C2776694085 @default.
• W1840478974 hasConcept C2777288759 @default.
• W1840478974 hasConcept C2908647359 @default.
• W1840478974 hasConcept C29730261 @default.
• W1840478974 hasConcept C42219234 @default.
• W1840478974 hasConcept C71924100 @default.
• W1840478974 hasConcept C90924648 @default.
• W1840478974 hasConcept C99454951 @default.
• W1840478974 hasConceptScore W1840478974C112705442 @default.
• W1840478974 hasConceptScore W1840478974C126322002 @default.
• W1840478974 hasConceptScore W1840478974C126894567 @default.
• W1840478974 hasConceptScore W1840478974C141071460 @default.
• W1840478974 hasConceptScore W1840478974C2776694085 @default.
• W1840478974 hasConceptScore W1840478974C2777288759 @default.
• W1840478974 hasConceptScore W1840478974C2908647359 @default.
• W1840478974 hasConceptScore W1840478974C29730261 @default.
• W1840478974 hasConceptScore W1840478974C42219234 @default.
• W1840478974 hasConceptScore W1840478974C71924100 @default.
• W1840478974 hasConceptScore W1840478974C90924648 @default.
• W1840478974 hasConceptScore W1840478974C99454951 @default.
• W1840478974 hasIssue "9" @default.
• W1840478974 hasLocation W18404789741 @default.
• W1840478974 hasLocation W18404789742 @default.
• W1840478974 hasOpenAccess W1840478974 @default.
• W1840478974 hasPrimaryLocation W18404789741 @default.
• W1840478974 hasRelatedWork W1586374228 @default.
• W1840478974 hasRelatedWork W1990335353 @default.
• W1840478974 hasRelatedWork W2003938723 @default.
• W1840478974 hasRelatedWork W2047967234 @default.
• W1840478974 hasRelatedWork W2118496982 @default.
• W1840478974 hasRelatedWork W2364998975 @default.
• W1840478974 hasRelatedWork W2369162477 @default.
• W1840478974 hasRelatedWork W2439875401 @default.
• W1840478974 hasRelatedWork W4238867864 @default.
• W1840478974 hasRelatedWork W2525756941 @default.
• W1840478974 hasVolume "13" @default.
• W1840478974 isParatext "false" @default.
• W1840478974 isRetracted "false" @default.
• W1840478974 magId "1840478974" @default.
• W1840478974 workType "article" @default.